These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 14607388)

  • 1. Reducing the burden of affective disorders: is evidence-based health care affordable?
    Sanderson K; Andrews G; Corry J; Lapsley H
    J Affect Disord; 2003 Nov; 77(2):109-25. PubMed ID: 14607388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence-based care for alcohol use disorders is affordable.
    Corry J; Sanderson K; Issakidis C; Andrews G; Lapsley H
    J Stud Alcohol; 2004 Jul; 65(4):521-9. PubMed ID: 15376827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modelling the population cost-effectiveness of current and evidence-based optimal treatment for anxiety disorders.
    Issakidis C; Sanderson K; Corry J; Andrews G; Lapsley H
    Psychol Med; 2004 Jan; 34(1):19-35. PubMed ID: 14971624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utilising survey data to inform public policy: comparison of the cost-effectiveness of treatment of ten mental disorders.
    Andrews G; Issakidis C; Sanderson K; Corry J; Lapsley H
    Br J Psychiatry; 2004 Jun; 184():526-33. PubMed ID: 15172947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence-based medicine is affordable: the cost-effectiveness of current compared with optimal treatment in rheumatoid and osteoarthritis.
    Andrews G; Simonella L; Lapsley H; Sanderson K; March L
    J Rheumatol; 2006 Apr; 33(4):671-80. PubMed ID: 16541479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of current and optimal treatment for schizophrenia.
    Andrews G; Sanderson K; Corry J; Issakidis C; Lapsley H
    Br J Psychiatry; 2003 Nov; 183():427-35; discussion 436. PubMed ID: 14594918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using epidemiological data to model efficiency in reducing the burden of depression*.
    Andrews G; Sanderson K; Corry J; Lapsley HM
    J Ment Health Policy Econ; 2000 Dec; 3(4):175-186. PubMed ID: 11967454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of current and optimal treatment for adult asthma.
    Simonella L; Marks G; Sanderson K; Andrews G
    Intern Med J; 2006 Apr; 36(4):244-50. PubMed ID: 16640742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mental health care system optimization from a health-economics perspective: where to sow and where to reap?
    Lokkerbol J; Weehuizen R; Mavranezouli I; Mihalopoulos C; Smit F
    J Ment Health Policy Econ; 2014 Jun; 17(2):51-60. PubMed ID: 25153093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs of schizophrenia and other psychoses in urban Australia: findings from the Low Prevalence (Psychotic) Disorders Study.
    Carr VJ; Neil AL; Halpin SA; Holmes S; Lewin TJ
    Aust N Z J Psychiatry; 2003 Feb; 37(1):31-40. PubMed ID: 12534654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing cost-effectiveness in mental health: family interventions for schizophrenia and related conditions.
    Mihalopoulos C; Magnus A; Carter R; Vos T
    Aust N Z J Psychiatry; 2004 Jul; 38(7):511-9. PubMed ID: 15255823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing cost-effectiveness in mental health: helping policy-makers prioritize and plan health services.
    Vos T; Haby MM; Magnus A; Mihalopoulos C; Andrews G; Carter R
    Aust N Z J Psychiatry; 2005 Aug; 39(8):701-12. PubMed ID: 16050924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis and comparative evaluations of the costs of supports and treatments of schizophrenia, affective psychosis, paranoia and neurosis].
    Grassi A; Bruni R; Pileggi F; Chiappelli M; Boldrini M; Franceschi E; Scarafoni D
    Epidemiol Psichiatr Soc; 2001; 10(2):115-24. PubMed ID: 11526793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. National estimates of health services expenditures for children with behavioral disorders: an analysis of the medical expenditure panel survey.
    Guevara JP; Mandell DS; Rostain AL; Zhao H; Hadley TR
    Pediatrics; 2003 Dec; 112(6 Pt 1):e440. PubMed ID: 14654642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mental health expenditure in Australia: time for affirmative action.
    Hickie IB; Davenport TA; Luscombe GM
    Aust N Z J Public Health; 2006 Apr; 30(2):119-22. PubMed ID: 16681330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of cognitive-behavioural therapy and drug interventions for major depression.
    Vos T; Corry J; Haby MM; Carter R; Andrews G
    Aust N Z J Psychiatry; 2005 Aug; 39(8):683-92. PubMed ID: 16050922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost of treating seriously mentally ill persons with HIV following highly active retroviral therapy (HAART).
    Rothbard AB; Lee S; Blank MB
    J Ment Health Policy Econ; 2009 Dec; 12(4):187-94. PubMed ID: 20195006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost of schizophrenia treatment in Taiwan.
    Lang HC; Su TP
    Psychiatr Serv; 2004 Aug; 55(8):928-30. PubMed ID: 15292543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The economic burden of affective disorders.
    Rice DP; Miller LS
    Adv Health Econ Health Serv Res; 1993; 14():37-53. PubMed ID: 10172899
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.